Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 3 Compare versions History 10 Sponsors

No sponsors recorded.

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base Passed First Chamber — base rate 16%, measured from US's completed sessions
Momentum +5 73/100 from the pace of recorded action
Time since last action -22 167 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.